Bigfoot Biomedical Stock
Medical Device Company
Sign up today and learn more about Bigfoot Biomedical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Bigfoot Biomedical Stock
Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.
Investors
Cormorant Asset Management
Abbott Biotech Ventures
JDRF T1D Fund
Janus Capital Group
Quadrant Capital Advisors
Funding History
November 2014 | $2.0M |
---|---|
October 2016 | $35.5M |
December 2017 | $37.0M |
March 2018 | $18.0M |
January 2020 | $45.0M |
Management
Chief Executive Officer
Brewer Jeffrey
Chief Financial Officer
Brett Hale
Chief Operating Officer
Ian Hanson
Press
thefly - Sep, 22 2023
Abbott completes acquisition of Bigfoot Biomedicalmpo-mag - Sep, 7 2023
Abbott and Bigfoot Biomedical Finally Get Hitchedfiercebiotech - Sep, 7 2023
Abbott tracks down Bigfoot Biomedical in deal to combine diabetes techseekingalpha - Sep, 6 2023
Abbott acquires Bigfoot Biomedical, furthers growth of personalized solutions for diabeticsfiercebiotech - Mar, 31 2023
Bigfoot Biomedical steps up diabetes tech with acquisition of auto-adjusting insulin dosing algorithm